[Drug-induced hemolytic anemia].
Terada
Hideo
H
Department of Internal Medicine, St. Luke's International Hospital.
D000743:Anemia, Hemolytic / Q000139:chemically induced* / Q000175:diagnosis / Q000276:immunology / Q000628:therapy; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D000936:Antigen-Antibody Complex; D000998:Antiviral Agents / Q000009:adverse effects; D001323:Autoantibodies; D003937:Diagnosis, Differential; D005955:Glucosephosphate Dehydrogenase Deficiency; D006241:Haptens; D006463:Hemolytic-Uremic Syndrome; D006801:Humans; D008750:Methyldopa / Q000009:adverse effects; D010406:Penicillins / Q000009:adverse effects*; D011342:Procainamide / Q000009:adverse effects; D054328:Proton Pump Inhibitors / Q000009:adverse effects; D011697:Purpura, Thrombotic Thrombocytopenic; D011802:Quinidine / Q000009:adverse effects*; D012254:Ribavirin / Q000009:adverse effects
D000900:Anti-Bacterial Agents; D000936:Antigen-Antibody Complex; D000998:Antiviral Agents; D001323:Autoantibodies; D006241:Haptens; D010406:Penicillins; D054328:Proton Pump Inhibitors; D012254:Ribavirin; D008750:Methyldopa; D011802:Quinidine; D011342:Procainamide